Suppr超能文献

微小RNA 133B靶向肺癌中的促生存分子MCL-1和BCL2L2。

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.

作者信息

Crawford Melissa, Batte Kara, Yu Lianbo, Wu Xin, Nuovo Gerard J, Marsh Clay B, Otterson Gregory A, Nana-Sinkam Serge P

机构信息

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, DHLRI, 473 West 12th Avenue, Room 201, Columbus, OH 43210, USA.

出版信息

Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9. doi: 10.1016/j.bbrc.2009.07.143. Epub 2009 Aug 3.

Abstract

Lung cancer is the most frequent cause of cancer-related death in this country for men and women. MicroRNAs (miRNAs) are a family of small non-coding RNAs (approximately 21-25nt long) capable of targeting genes for either degradation of mRNA or inhibition of translation. We identified aberrant expression of 41 miRNAs in lung tumor versus uninvolved tissue. MiR-133B had the lowest expression of miRNA in lung tumor tissue (28-fold reduction) compared to adjacent uninvolved tissue. We identified two members of the BCL-2 family of pro-survival molecules (MCL-1 and BCL2L2 (BCLw)) as predicted targets of miR-133B. Selective over-expression of miR-133B in adenocarcinoma (H2009) cell lines resulted in reduced expression of both MCL-1 and BCL2L2. We then confirmed that miR-133B directly targets the 3'UTRs of both MCL-1 and BCL2L2. Lastly, over-expression of miR-133B induced apoptosis following gemcitabine exposure in these tumor cells. To our knowledge, this represents the first observation of decreased expression of miR-133B in lung cancer and that it functionally targets members of the BCL-2 family.

摘要

肺癌是该国男性和女性癌症相关死亡的最常见原因。微小RNA(miRNA)是一类小的非编码RNA(长度约为21-25个核苷酸),能够靶向基因以降解mRNA或抑制翻译。我们在肺肿瘤组织与未受累组织中鉴定出41种miRNA的异常表达。与相邻的未受累组织相比,miR-133B在肺肿瘤组织中的miRNA表达最低(降低了28倍)。我们鉴定出促生存分子BCL-2家族的两个成员(MCL-1和BCL2L2(BCLw))为miR-133B的预测靶标。在腺癌(H2009)细胞系中选择性过表达miR-133B导致MCL-1和BCL2L2的表达均降低。然后我们证实miR-133B直接靶向MCL-1和BCL2L2的3'非翻译区(3'UTR)。最后,在这些肿瘤细胞中,吉西他滨处理后过表达miR-133B可诱导细胞凋亡。据我们所知,这是首次观察到miR-133B在肺癌中表达降低,并且它在功能上靶向BCL-2家族成员。

相似文献

1
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.
Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9. doi: 10.1016/j.bbrc.2009.07.143. Epub 2009 Aug 3.
4
Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer.
Cancer Lett. 2015 Dec 1;369(1):58-66. doi: 10.1016/j.canlet.2015.06.028. Epub 2015 Aug 11.
5
MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R.
Oncogene. 2013 Jun 20;32(25):3071-9. doi: 10.1038/onc.2012.318. Epub 2012 Jul 23.
6
MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
Exp Cell Res. 2016 May 1;343(2):135-147. doi: 10.1016/j.yexcr.2016.03.027. Epub 2016 Apr 19.
7
Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1.
Apoptosis. 2013 Jul;18(7):896-909. doi: 10.1007/s10495-013-0841-7.
9
Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Cell Death Differ. 2015 Dec;22(12):2098-106. doi: 10.1038/cdd.2015.73. Epub 2015 Jun 5.
10
MicroRNA-16 functions as a tumor-suppressor gene in oral squamous cell carcinoma by targeting AKT3 and BCL2L2.
J Cell Physiol. 2018 Dec;233(12):9447-9457. doi: 10.1002/jcp.26833. Epub 2018 Aug 22.

引用本文的文献

1
MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma.
Front Oncol. 2025 Jun 20;15:1577859. doi: 10.3389/fonc.2025.1577859. eCollection 2025.
2
Investigating miR-9 and miR-222 in CSF and Plasma of Neuroblastoma Patients as Metastatic and Apoptotic-Related Markers.
Cell Biochem Biophys. 2025 Jun;83(2):1605-1615. doi: 10.1007/s12013-024-01570-9. Epub 2024 Dec 12.
3
Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on heart failure.
Front Immunol. 2022 Nov 7;13:1052850. doi: 10.3389/fimmu.2022.1052850. eCollection 2022.
4
Apoptosis evasion via long non-coding RNAs in colorectal cancer.
Cancer Cell Int. 2022 Sep 8;22(1):280. doi: 10.1186/s12935-022-02695-8.
5
The paradigm of drug resistance in cancer: an epigenetic perspective.
Biosci Rep. 2022 Apr 29;42(4). doi: 10.1042/BSR20211812.
6
Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.
Mol Ther Oncolytics. 2021 Dec 22;24:262-287. doi: 10.1016/j.omto.2021.12.015. eCollection 2022 Mar 17.
7
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers.
Biochem Soc Trans. 2021 Nov 1;49(5):2397-2410. doi: 10.1042/BST20210750.
8
The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors.
Int J Mol Sci. 2021 Aug 9;22(16):8569. doi: 10.3390/ijms22168569.
9
Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
FEBS J. 2022 Oct;289(20):6209-6234. doi: 10.1111/febs.16136. Epub 2021 Aug 2.
10
Epigenetic Deregulation of Apoptosis in Cancers.
Cancers (Basel). 2021 Jun 27;13(13):3210. doi: 10.3390/cancers13133210.

本文引用的文献

1
MicroRNAs in the pathogenesis of Lung Cancer.
J Thorac Oncol. 2009 Aug;4(8):1028-34. doi: 10.1097/JTO.0b013e3181a99c77.
2
Cancer statistics, 2009.
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
3
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Pharmacogenomics. 2009 Jan;10(1):69-80. doi: 10.2217/14622416.10.1.69.
4
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Am J Respir Cell Mol Biol. 2009 Jul;41(1):14-23. doi: 10.1165/rcmb.2008-0320OC. Epub 2008 Dec 18.
6
High-throughput real-time PCR.
Methods Mol Biol. 2008;429:89-98. doi: 10.1007/978-1-60327-040-3_7.
7
Analyzing real-time PCR data by the comparative C(T) method.
Nat Protoc. 2008;3(6):1101-8. doi: 10.1038/nprot.2008.73.
10
Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
J Biol Chem. 2008 Jul 18;283(29):20045-52. doi: 10.1074/jbc.M801035200. Epub 2008 May 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验